Unlock instant, AI-driven research and patent intelligence for your innovation.

Medicinal composition and application thereof to preparation of drug for treating virus infection of flavivirus

A composition and medicine technology, applied in the field of medicine, to achieve the effect of enhancing therapeutic effect and treating flavivirus infection

Active Publication Date: 2018-05-08
武汉百药联科科技有限公司
View PDF0 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Currently, there is no precedent for the combination of boronic acid or epoxyketone 20S proteasome inhibitors and biotin for the treatment of flavivirus infection

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Medicinal composition and application thereof to preparation of drug for treating virus infection of flavivirus
  • Medicinal composition and application thereof to preparation of drug for treating virus infection of flavivirus
  • Medicinal composition and application thereof to preparation of drug for treating virus infection of flavivirus

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0038] As an example of the pharmaceutical composition of the present invention, the pharmaceutical composition of this embodiment is: the pharmaceutical combination includes bortezomib and biotin, and the weight ratio of bortezomib and biotin is 1:10.

[0039]The bortezomib in this embodiment can be replaced by other boric acid 20S proteasome inhibitors, such as bortezomib pharmaceutically acceptable salts, exazomib or pharmaceutically acceptable salts thereof.

Embodiment 2

[0041] As an example of the pharmaceutical composition of the present invention, the pharmaceutical composition of this embodiment is: the pharmaceutical combination includes carfilzomib and biotin, and the weight ratio of carfilzomib and biotin is 1:2.5.

[0042] Carfilzomib in this embodiment can be replaced by other epoxyketone 20S proteasome inhibitors, such as a pharmaceutically acceptable salt of carfilzomib.

[0043] The medicine involved in the present invention can be prepared in any form, such as granule, powder, tablet, capsule, injection or oral liquid.

[0044] The medicament of the present invention may further include one or more pharmaceutically acceptable carriers or diluents, which will be properly formulated for administration, and the pharmaceutically acceptable diluents may be water, Ringer's solution, buffered saline ; The pharmaceutically acceptable carrier is glucose, maltodextrin, glycerin, mannitol, sorbitol, dextrin, lactose, gelatin, calcium sulfate...

Embodiment 3

[0045] Example 3 Application of biotin combined with bortezomib in the treatment of mice infected with Japanese encephalitis virus

[0046] 1. Establishment of a mouse model infected with Japanese encephalitis virus

[0047] 1. Experimental materials:

[0048] (1) Experimental animals: four-week-old Balb / c female mice.

[0049] (2) Strain: JEV P3 strain.

[0050] (3) Other reagents:

[0051] 1) 0.01M PBS buffer: weigh NaH 2 PO4 0.593g, Na 2 HPO4 5.802g, NaCl 17.0g, deionized water (ddH 2 O) Dilute to 2L, store at room temperature for later use.

[0052] 2) DMEM basal medium: a bottle of DMEM powder, weighed NaHCO 3 3.7g, HEPES 5.95g, add 800mLddH 2 O, stir well to dissolve, dilute to 1000mL, sterilize with a 0.22μm filter, and store at 4°C for later use.

[0053] 2. Experimental steps

[0054] Mice were injected intraperitoneally with 10 6 PFU Japanese encephalitis virus, the mice in the control group were intraperitoneally injected with the same dose of DMEM mediu...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a medicinal composition and application thereof to the preparation of a drug for treating virus infection of flavivirus. The medicinal composition is prepared from biotin and a20S proteasome inhibitor, wherein the 20S proteasome inhibitor is a boric acid or epoxy ketone 20S proteasome inhibitor. According to the application, through establishing animal models of mice infected with Japanese B encephalitis viruses, a survival rate and pathological sections of brain tissue of the mice treated by using the medicinal composition are analyzed; meanwhile, a health mouse and amouse which is infected with the Japanese B encephalitis virus but is not subsequently treated by using the medicinal composition are used as references; through data statistic analysis, the medicinal composition has a certain treatment effect on the virus infection of the flavivirus. The invention also adopts a personalized administration method based on gene expression data of a patient inflected with the flavivirus; the effectiveness of the medicinal composition is identified, and a final result shows that the medicinal composition has an obvious treatment effect on the virus infection ofthe flavivirus.

Description

technical field [0001] The invention relates to the technical field of medicine, in particular to a pharmaceutical composition and its application in the preparation of medicines for treating flavivirus infection. Background technique [0002] The Flavivirus family (Flaviviridae) is an enveloped single-stranded positive-sense RNA virus, which is transmitted by blood-sucking arthropods (mosquitoes, ticks, sandflies, etc.) to cause infection. The flavivirus genus includes about 70 viruses, most of which are pathogens of zoonotic infectious diseases, such as Japanese encephalitis virus (Japanese encephalitis virus, JEV), West Nile virus (WNV), yellow fever Virus (Yellowfevervirus, YFV), Dengue virus (DENV) 1-4 types, Zika virus (Zika virus, ZIKV), etc. [0003] The gene of the flavivirus genus is a single-stranded positive-strand RNA, about 11kb in length, with a non-coding region (UTR) at the 5' end and a 3' end, a methylated cap structure at the 5' end, and a methylated cap ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K45/06A61K31/4188A61K38/05A61K31/69A61K38/08A61P31/14
CPCA61K31/4188A61K31/69A61K38/05A61K38/08A61K45/06A61K2300/00Y02A50/30
Inventor 张红雨吕博敏全源张青叶黄清
Owner 武汉百药联科科技有限公司
PatSnap Eureka logo

PatSnap Eureka turns technology decisions into work you can execute. Powered by our Innovation Knowledge Graph, it runs expert workflows across engineering, life sciences, materials and intellectual property. Get your review-ready output in minutes.

X (Twitter)LinkedInYouTubeSubstack

© 2026 PatSnap. All rights reserved. 

Terms of Service

 | 

Privacy policy

 | 

Modern Slavery Act Transparency Statement